CORV - Correvio Pharma Corp.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.3706
+0.0026 (+0.71%)
At close: 3:57PM EDT

0.3700 -0.00 (-0.16%)
After hours: 6:47PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3680
Open0.3720
Bid0.3626 x 2200
Ask0.3740 x 900
Day's Range0.3611 - 0.3790
52 Week Range0.2100 - 2.9800
Volume1,314,354
Avg. Volume6,786,071
Market Cap25.679M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.7950
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Correvio Obtains Interim Order For Plan Of Arrangement

      Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained an interim order from the Supreme Court of British Columbia (the "Court") authorizing the holding of an annual general and special meeting (the "Meeting") of the Securityholders (as defined below) and matters relating to the conduct of the Meeting.

    • Correvio Pharma (CORV) Reports Q4 Loss, Misses Revenue Estimates
      Zacks

      Correvio Pharma (CORV) Reports Q4 Loss, Misses Revenue Estimates

      Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

    • PR Newswire

      Correvio Reports Full Year 2019 Financial Results

      Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for the full year ended December 31, 2019 and commented on recent accomplishments and plans.

    • GlobeNewswire

      Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – CORV, TERP, IOTS, CBB

      NEW YORK, March 24, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders..

    • Business Wire

      CORREVIO PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Correvio Pharma Corp. - CORV

      Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Correvio Pharma Corp. (NasdaqGS: CORV) to ADVANZ PHARMA Corp. Limited. Under the terms of the proposed transaction, shareholders of Correvio will receive only $0.42 in cash for each share of Correvio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

    • ACCESSWIRE

      Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - TTPH, CORV

      Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - TTPH, CORV NEW YORK, NY / ACCESSWIRE / March 16, 2020 / Halper Sadeh LLP, a global investor rights law ...

    • PR Newswire

      ADVANZ PHARMA to Acquire Correvio

      Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced its entry into an arrangement agreement ("Arrangement Agreement") dated March 15, 2020, for ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA", TSX:ADVZ) to acquire all of the issued and outstanding shares of Correvio. The acquisition, which will be executed through ADVANZ PHARMA's wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), is expected to have a total purchase price of approximately US$76 million, which includes the repayment of certain Correvio indebtedness, pursuant to a plan of arrangement under the Canada Business Corporations Act (the "Arrangement").

    • Benzinga

      Benzinga Pro's Top 5 Stocks To Watch For Tues., Mar. 10, 2020: FXI, TSLA, OXY, CORV, CLDR

      Benzinga Pro's Stocks To Watch For Tuesday * iShares China Large-Cap ETF (FXI) \- The most-active ETF reflecting price action in the broader Chinese markets, the FXI was up more than 3% in pre-market action. A Global Times report suggested the last patient was discharged from the Wuchang makeshift hospital in Wuhan on Tuesday. Additionally, Chinese President Xi declared victory over the coronavirus in the city of Wuhan. US futures were up about 4% and hit a limit up circuit breaker -- the opposite of what happened in pre-market action Monday morning. * Tesla (TSLA) \- The stock was up about 9% to over the $650 level. A report suggested Tesla plans to increase production capacity for certain parts at its Shanghai factory. * Occidental Petroleum (OXY) \- One of the hardest hit oil & gas stocks Monday amid the massive drop in crude oil prices, Occidental shares rebounded Tuesday. After the stock fell more than 50% on Monday, shares were up 23% Tuesday morning. More than 103 million shares were traded on Monday, compared to the stock's average daily volume of just 13 million shares. * Correvio Pharma (CORV) \- Shares were up 30% following news of a partnership with Hong Kong Teson Pharma Limited for an exclusive agreement for the commercialization of Aggrastat® for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. * Cloudera (CLDR) \- Will report Q4 results after the market close on Tuesday. Analysts expect a loss of about $0.03/share on sales of about $202 million.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 18, 2020: AAPL, WMT, TSLA, FLR, SPWR * Benzinga Pro's Top 5 Stocks To Watch For Fri., Feb. 14, 2020: TSLA, ROKU, CRON, YELP, AMD(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • PR Newswire

      Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China

      Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limited (Teson), a privately-held pharmaceutical company, today announced that Correvio International Sàrl, a wholly owned subsidiary of Correvio, and Teson have entered into an exclusive agreement for the commercialization of Aggrastat® (tirofiban hydrochloride). The agreement covers the territories of mainland China (excluding Taiwan and Hong Kong) and Macau. Aggrastat® is Correvio's marketed asset for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).

    • When Can We Expect A Profit From Correvio Pharma Corp. (TSE:CORV)?
      Simply Wall St.

      When Can We Expect A Profit From Correvio Pharma Corp. (TSE:CORV)?

      Correvio Pharma Corp.'s (TSE:CORV): Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing...

    • Will Correvio Pharma (CORV) Report Negative Q4 Earnings? What You Should Know
      Zacks

      Will Correvio Pharma (CORV) Report Negative Q4 Earnings? What You Should Know

      Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    • PR Newswire

      Correvio Responds to Market Activity

      At the request of Investment Industry Regulatory Organization of Canada ("IIROC"), Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV) (the "Company") wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares. As announced on December 11, 2019, the Company is engaged in a process to explore strategic options to maximize stakeholder value which is ongoing. Correvio has not set a timetable for completion of this review process and the Company does not intend to comment further unless or until the Board of Directors has approved a definitive course of action, the review process is concluded, or it is determined that other disclosure is appropriate.

    • ACCESSWIRE

      FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

      LOS ANGELES, CA / ACCESSWIRE / February 10, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

    • GlobeNewswire

      INVESTOR ALERT - Correvio Pharma Corp. (CORV) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

      This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting the Resubmitted New Drug Application ("NDA") for Brinavess did not minimize the significant health and safety issues observed in connection with the drug's original NDA; (2) the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) as a result, Correvio's public statements were materially false and misleading at all relevant times.

    • ACCESSWIRE

      CORV FINAL DEADLINE: ROSEN, INVESTOR COUNSEL, Reminds Correvio Pharma Corp. Investors of Important February 10 Deadline in Securities Class Action

      NEW YORK, NY / ACCESSWIRE / February 8, 2020 / Rosen Law Firm reminds purchasers of the securities of Correvio Pharma Corp. between October 23, 2018 and December 5, 2019, inclusive (the "Class Period") ...

    • ACCESSWIRE

      FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

      LOS ANGELES, CA / ACCESSWIRE / February 7, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

    • ACCESSWIRE

      FINAL DEADLINE FEBRUARY 10: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

      LOS ANGELES, CA / ACCESSWIRE / February 6, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" ...

    • GlobeNewswire

      SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Correvio Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – CORV

      Pomerantz LLP announces that a class action lawsuit has been filed against Correvio Pharma Corporation (“Correvio” or the “Company”) (NASDAQ: CORV) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 19-cv-11361, is on behalf of a class consisting of investors who purchased or otherwise acquired Correvio securities between October 23, 2018 and December 5, 2019, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

    • GlobeNewswire

      Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Correvio Pharma Corporation

      If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On December 6, 2019, U.S. Food and Drug Administration (“FDA”) staffers who reviewed the Company’s resubmitted New Drug Application (“NDA”) for Brinavess found that the drug’s benefits did not offset its risks because Brinavess was associated with “serious liabilities” including irregular heartbeat, low blood pressure, and death.

    • ACCESSWIRE

      5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

      LOS ANGELES, CA / ACCESSWIRE / February 5, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020.